Hepatocellular carcinoma (controls excluding all cancers)

C3_HEPATOCELLU_CARC_EXALLC

No definition available.

Endpoint definition

FinnGen phenotype data

individuals

diagram downward connector

Apply sex-specific rule None

diagram downward connector

Check conditions None

diagram downward connector
diagram bullet

Check pre-conditions, main-only, mode, registry filters

Cause of death: ICD-10 C22.0&
Cancer registry: Topography ICD-O-3 C22
Cancer registry: Morphology ICD-O-3 817[0-5]
Cancer registry: Behaviour codes 3

2 out of 7 registries used, show all original rules.

-

diagram downward connector

Check minimum number of events None

-

diagram downward connector

Include endpoints None

-

diagram downward connector
diagram bullet diagram downward connector

Remove individuals based on genotype QC

500

diagram downward connector
C3_HEPATOCELLU_CARC_EXALLC

Control definitions

Control exclude C3_CANCER, C3_CANCER_WIDE

Extra metadata

First used in FinnGen datafreeze DF8

Similar endpoints

List of similar endpoints to Hepatocellular carcinoma (controls excluding all cancers) based on the number of shared cases.

Venn diagram with an highlighted set fully inside another set Broader endpoints:

Venn diagram with a set fully inside an highlighted set Narrower endpoints:

Show all endpoint correlations

Summary Statistics

Key figures

All Female Male
Number of individuals 500 57 443
Unadjusted prevalence (%) 0.12 0.02 0.24
Mean age at first event (years) 71.83 71.87 71.82

Mortality

Follow-up Absolute risk HR [95% CI] p N
1998–2019 - - - -
15 years - - - -
5 years - - - -
1 year - - - -

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Correlations

Index endpoint: C3_HEPATOCELLU_CARC_EXALLC – Hepatocellular carcinoma (controls excluding all cancers)
GWS hits: 2

Survival analyses between endpoints

Plot

before Hepatocellular carcinoma (controls excluding all cancers)
after Hepatocellular carcinoma (controls excluding all cancers)

loading spinner Loading survival analyses plot

Drugs most likely to be purchased after Hepatocellular carcinoma (controls excluding all cancers)

Endpoint not on priority list, no data to show.